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Abstract: The discovery of catalytic nucleic acids (CNAs) has provided scientists with 
valuable tools for the identification of new therapies for several untreated diseases through 
down regulation or modulation of endogenous gene expression involved in these ailments. 
These CNAs aim either towards the elimination or repair of pathological gene expression. 
Ribozymes, a class of CNAs, can be mostly used to down-regulate (by RNA cleavage) or 
repair (by RNA trans-splicing) unwanted gene expression involved in disease. DNAzymes, 
derived by in vitro selection processes are also able to bind and cleave RNA targets and 
therefore down-regulate gene expression. The purpose of this review is to present and 
discuss several applications of ribozymes and DNAzymes in muscle and brain. There are 
several diseases which affect muscle and brain and catalytic nucleic acids have been used 
as tools to target specific cellular transcripts involved in these groups of diseases. 
Keywords: catalytic nucleic acids; ribozyme; DNAzyme; brain; muscle 
 
1. Introduction  
Selective gene silencing by catalytic nucleic acids is a field that has been used with great success 
for studying natural processes in muscle and brain. Furthermore, these catalytic nucleic acids have 
been widely used for establishing novel gene therapy approaches for many muscle and brain diseases. 
OPEN ACCESS
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In most cases, catalytic nucleic acids aim towards either the elimination or repair of pathological 
transcripts. Catalytic nucleic acids can be separated into two main categories: ribozymes and 
DNAzymes. Ribozymes, the most extensively studied of the catalytic nucleic acids, exist in a range of 
distinct categories of naturally occurring catalytic RNA. These include a series of small ribozymes 
important for the rolling circle replication of viroid genomes, such as hammerhead and hairpin 
ribozymes [1-3], group I introns [4-6], the RNA component of RNase P [7], and hepatitis delta virus 
ribozyme [8]. Several recent reviews have described and discussed the various catalytic nucleic acids 
[6,9,10]. The hammerhead, hairpin and hepatitis delta virus (HDV) ribozyme motifs can be 
characterized by their ability for self-cleavage of a particular phosphodiester bond [9,11]. 
Hammerhead ribozymes have the ability to suppress gene expression through specific cleavage of 
RNA molecules [9]. Group I Intron ribozymes can be characterized by their capacity for self-splicing 
by cleavage and ligation of phosphodiester bonds [6,11]. Group I intron ribozymes can be designed to 
act in trans by recognition and separation of RNA molecules in a sequence specific manner, and 
ligation of a new RNA sequence to the separated RNA molecules [6]. DNAzymes, by contrast to 
ribozymes, have not been observed in nature and are derived by in vitro selection processes. One of the 
most characterized DNAzyme is the 10-23 subtype consisting of a cation-dependent catalytic core of 
15 deoxyribonucleotides that binds to and cleaves its target RNA between an unpaired purine and 
paired pyrimidine through a de-esterification reaction [10,12]. The catalytic activity and specificity of 
both ribozymes and DNAzymes has been extensively characterized in vitro and in cell culture systems. 
A wide range of chemical modifications has allowed the synthesis of oligonucleotides with in vivo 
stability approaching that of most conventional drugs [13]. 
Beside ribozymes and DNAzymes, advances in molecular genetics have revealed new tools for 
selective gene silencing. Small interfering RNAs (siRNAs) are single strands of RNA, approximately 
20 nucleotides long, which are able to target, cleave and inactivate specific mRNAs [14]. This 
powerful tool for the down regulation of mRNA levels is widely used for the potential treatment of 
many diseases [15,16]. The high specificity and suppression of pathogenic RNA by using siRNA 
technology proves to be of high expectations. Nevertheless, like ribozymes and DNAzymes, siRNA 
technology shows some limitation on the selectivity, delivery and stability [14]. Efficient delivery and 
distribution of oligonucleotide compounds both intracellularly and in vivo remains a critical challenge 
for successful transition from the laboratory to the clinic.  
Beside siRNAs, antisense oligonucleotides have been used to inhibit gene expression levels both in 
vitro and in vivo [17]. Antisense oligonucleotides usually consist of 18-25 bases long in antisense 
orientation to the mRNA of interest. Hybridization of the antisense oligo to the target mRNA results in 
RNAse H cleavage of the mRNA and prevents protein translation thereby blocks gene expression [18]. 
During the  last twenty years, antisense oligonucleotides have been widely used in basic research, 
genomics and drug discovery. This review will focus on the use of ribozymes and DNAzymes towards 
the study and potential therapy of muscle and brain diseases. 
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2. The Use of Ribozymes and DNAzymes in Muscle  
Ribozymes and DNAzymes have been widely used towards the better understanding and therapy of 
various skeletal and smooth muscle disorders. Myotonic dystrophy type I, myotonia congenita and 
neuromuscular junction abnormalities, restenosis of coronary arteries and hypertension are some of the 
disorders that scientists introduced the use of ribozymes and DNAzymes (Figure 1).  
Figure 1. Strategies for the study or therapy of muscle and brain diseases by using 
ribozymes and DNAzymes.  
 
 
In this review, we will focus on different strategies implicating the function of ribozymes and 
DNAzymes in the pathomechanisms and therapy of these disorders (Table 1).  
Table 1. Ribozymes and DNAzymes used for the elimination or repair of pathogenic gene 
expression involved in different muscle and brain diseases.  
Ribozyme-DNAzyme Disease Gene-Gene target Reference 
Hammerhead ribozyme 
 
 
Vascular smooth muscle 
cell hypertrophy-
Restenosis 
Leukocyte-type 12-
lipoxygenase (12-LO) 
Gu, J.L., et.al. Circ. Res. 1995, 77, 
14-20 
Hammerhead ribozyme 
 
 
Vascular smooth muscle 
cell hypertrophy-
Restenosis 
Proto-oncogene c-myb Jarvis, T.C., et al. RNA, 1996,  2, 
419-428. 
MUSCLE 
DISEASE
BRAIN 
DISEASE
Down-regulation of 
gene expression e.g. 
Hammerhead 
ribozymes, DNAzymes 
Repair of detective 
gene expression e.g. 
Group I intron 
ribozyme 
Study 
gene 
function 
Genetic 
therapies 
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Table 1. Cont. 
Hammerhead ribozyme 
 
Vascular smooth muscle 
cell hypertrophy-
Restenosis 
Cyclin E and Cyclin 
E2F1 
Grassi, G., et al., J Gene Med, 
2005. 7(9): p. 1223-1234. 
Hammerhead ribozyme 
 
Myotonic Dystrophy 
type 1 (DM1) 
Mutant DMPK 3’ 
UTR 
Langlois, M.A., et al., Mol Ther, 
2003. 7(5 Pt 1): p. 670-680. 
Group I intron ribozyme Myotonic Dystrophy 
type 1 (DM1) 
Mutant DMPK 3’ 
UTR 
Phylactou, L.A., et al., Nat Genet, 
1998. 18(4): p. 378-381. 
Hammerhead ribozyme 
 
Slow channel congenital 
myasthenic syndrome 
Acetylcholine receptor 
(AchR) 
Abdelgany, A., et al.,  
J RNAi Gene Silencing, 
2005. 1(1): p. 26-31. 
DNAzyme Slow channel congenital 
myasthenic syndrome 
Acetylcholine receptor 
(AchR) 
Abdelgany, A., et al.,  
J RNAi Gene Silencing, 2005. 
1(1): p. 32-37. 
DNAzyme Huntington’s  Huntingtin (HTT) Yen, L., et al., Ann Neurol, 1999. 
46(3): p. 366-373. 
Hammerhead ribozyme 
 
Alzheimer's β-Secretase Nawrot, B., et al.,  
Eur J Biochem, 2003.  
270(19): p. 3962-3970. 
Hammerhead ribozyme 
 
 
Alzheimer's Dihydrolipoamide 
succinyltransferase 
(DLST) 
Kanamori, T., et al., 
EMBO J, 2003.  
22(12): p. 2913-2923. 
Hammerhead ribozyme 
 
Parkinson’s a-Synuclein Hayashita-Kinoh, H., et al., 
Biochem Biophys Res Commun, 
2006. 341(4): p. 1088-1095. 
Hammerhead ribozyme 
 
Glioblastomas Pleiotrophin (PTN) Grzelinski, M., et al., Int J Cancer, 
2005. 117(6): p. 942-951. 
Hammerhead ribozyme 
 
Glioblastomas Pleiotrophin (PTN) 
and anaplastic 
lymphoma kinase 
(ALK) 
Grzelinski, M., et al., Neoplasia, 
2009. 11(2): p. 145-156. 
Hammerhead ribozyme 
 
Encephalitis Japanese encephalitis 
virus (JEV) 
Appaiahgari, M.B. and S. Vrati. 
Mol Ther, 2007. 15(9): p. 1593-
1599. 
 
The vascular smooth muscle cell in mature animals is a highly specialized cell whose principal 
function is contraction and regulation of blood vessel tone-diameter, blood pressure, and blood flow 
distribution. However, abnormal environmental signals can lead to adverse phenotypic switching and 
acquisition of characteristics of smooth muscle cell that can contribute to the development and/or 
progression of vascular disease [19,20]. Several attempts have been reported which utilised catalytic 
nucleic acids in smooth muscle cells. References to several reports which demonstrate the application 
and usefulness of ribozymes and DNAzymes in smooth muscle cells are presented below. 
Angiotensin II (Ang II) plays an important role in the development of hypertension and 
atherosclerosis by inducing vascular smooth muscle cell growth and synthesis of aldosterone [21,22]. 
Activation of Leukocyte-type 12-lipoxygenase (12-LO) has been proposed to be an important 
mechanism for AngII by inducing hypertrophy of vascular smooth muscle cells. This finding prompted 
scientists to design a chimeric RNA hammerhead ribozyme against the first GUC sequence at 
nucleotide 7 of porcine leukocyte 12-LO mRNA. The ribozyme was transfected into porcine aortic 
vascular smooth muscle cells, causing a significant decrease of endogenous porcine leukocyte-type 12-
LO mRNA and protein levels [23]. Downregulation of 12-LO levels, have the potential to protect 
vascular smooth muscle cells from hypertrophy [24]. The results from this study indicated the 
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feasibility of using new ribozyme technology to study the specific effects of a gene pathway in vascular 
disease and the potential therapies. 
Proliferation of injured smooth muscle cells contributes to the reocclusion or restenosis of coronary 
arteries that often occurs following angioplasty procedures. Coronary angioplasty is an effective 
procedure used in order to open occluded vessels. However, in spite of a number of technical 
improvements in the procedure, post-operative occlusion of arteries, or restenosis, still occurs. It is 
widely believed that by preventing the injury-induced activation and proliferation of medial smooth 
muscle cells after angioplasty, intiminal thickening and restenosis could be prevented [25]. In an 
attempt to inhibit smooth muscle cell proliferation, Jarvis et al. described the activity of several 
ribozymes targeting c-myb mRNA. Hammerhead ribozymes were capable of cleaving c-myb RNA and 
as a result inhibit smooth muscle cell proliferation [26]. This finding indicated that hammerhead 
ribozymes have the potential to inhibit the hyperproliferation of smooth muscle cells that occurs in 
many patients after coronary angioplasty. In another attempt to prevent restenosis in coronary arteries, 
Grassi et al. explored the use of hammerhead ribozymes as tools to knock down specific activators of 
cell proliferation. They designed two specific hammerhead ribozymes to inhibit the mRNA levels of 
cyclin E and E2F1, two potent activators of cell proliferation which cooperate to promote the G1 to S 
phase transition [27,28]. After transfecting these hammerhead ribozymes within coronary smooth 
muscle cells, mRNA and protein levels of cyclin E and E2F1 were significantly reduced. Furthermore, 
the coronary smooth muscle cell growth was dramatically shut down and almost completely prevented 
when the two hammerhead ribozymes were administered together [29].  
 Ribozymes and DNAzymes have been also used as tools to target defects in neuromuscular 
diseases. Myotonic Dystrophy type 1 (DM1) is a degenerative neuromuscular disease characterised by 
a large CTG repeat expansion situated in the 3’ UTR of the DMPK gene. The mutant DMPK 3’ UTR 
RNA containing the CUG expansion accumulate to form RNA foci in the nucleus of DM1 cells 
[30,31]. These RNA foci interact with nuclear RNA binding proteins preventing their export from the 
nucleus [32,33]. The fact that most of the disease pathomechanisms involve mutant RNA foci and their 
interactions to various binding proteins, prompted researchers to create specific ribozymes for the 
destruction of the mutant RNA. Langlois et al. identified most of the accessible ribozyme target sites 
in the 3’ UTR of the DMPK mRNA and designed a hammerhead ribozyme to cut the most accessible 
site. The use of these hammerhead ribozyme significantly reduced the number of mutant DMPK 
mRNA-containing nuclear foci in human DM1 myoblasts. The reduction of mutant DMPK mRNA and 
nuclear foci had as an effect the partial restoration of insulin receptor isoform B expression in DM1 
myoblasts [34].  
Another approach was the use of specific ribozymes for the repair of the expanded repeat. 
Phylactou et al. designed a group I intron ribozyme in order to modify the CUG repeat expansion at 
the 3’ UTR of the human DMPK transcripts. This group I intron ribozyme showed to be capable of 
ligating a small mRNA fragment, contained within the ribozyme, to a simple DMPK-target RNA in 
vitro. It also modified a larger target transcript, leading to replacement of twelve repeats with five 
repeats, both in vitro and in mammalian cells [35].  
The mutant canine skeletal muscle chloride channel (cClC-1) mRNA transcript that causes the 
inherited disorder myotonia congenita, prompted scientists to further investigate the feasibility of RNA 
repair using specific ribozymes. Rogers et al. designed a modified Tetrahymena ribozyme to mediate 
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trans-splicing repair of the mutant canine skeletal muscle chloride channel (cClC-1) mRNA 
transcripts. The ribozyme was able to target the mutant mRNA and replace the mutant containing 3’ 
portion by trans-splicing the corresponding wild type sequence. Furthermore, when the chloride 
channel function was examined in single cells, a wide range of electrophysiological activity was 
observed, with 18% of cells exhibiting significant functional restoration and some cells exhibiting 
complete rescue of the biophysical phenotype [36]. 
The muscle acetylcholine receptor (AChR) is expressed at the neuromuscular junction, and plays 
the principal role in nerve to muscle signal transmission. A number of mutations have been 
characterised in the AChR -subunit gene which affect receptor function and give rise to slow channel 
congenital myasthenic syndrome [37,38]. Abdelgany et al. designed hammerhead ribozymes in order 
to target RNA transcripts from four different slow channel congenital myasthenic syndrome mutations. 
These hammerhead ribozymes were able to efficiently discriminate between mutant and wild type 
RNA transcripts that differ only by a single nucleotide substitution [39]. Furthermore, the ability of 
DNAzymes to cause allele-specific cleavage in transcripts where the mutation creates a putative 
cleavage site or full DNAzyme:target binding was tested. Alelle-specific cleavage was demonstrated in 
both cases under simulated physiological conditions [40]. 
3. The Use of Ribozymes and DNAzymes in Brain  
The use of ribozyme and DNAzyme strategies were also introduced in various brain disorders 
(Figure 1). Huntington’s, Alzheimer’s and Parkinson’s are some of brain diseases that ribozymes and 
DNAzymes were used for their study and therapy (Table 1). Huntington’s disease (HD) is a 
progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of 
thinking ability. The underlying cause of Huntington's disease is the inheritance of a copy of the gene 
encoding huntingtin with an expanded polyglutamine-encoding CAG repeat located within the 5′ end 
of the coding region [41]. The mutant huntingtin protein is expressed during development through 
adulthood, causes neuronal dysfunction, and ultimately cell death of neurons in the striatum. The 
neuropathology is present to a varying extent in other regions of the brain [41]. Yen et al. 
demonstrated the first effective destruction of the mutant huntingtin mRNA using a specific DNAzyme 
that was able to cleave the mutant huntingtin mRNA in a sequence-specific manner, that lead to 
significant reduction of mutant huntingtin protein expression in mammalian cells [42]. Therefore, with 
the reduction of the mutant huntingtin, several pathways associated with huntingtin were altered and 
less cellular toxicity was observed. Cellular and animal models showing significantly reduced 
huntingtin levels, reduce the severity of the disease, suggesting that HD might be reversible [43,44].  
Catalytic nucleic acids have been also used in Alzheimer's disease (AD). AD is a neurodegenerative 
disorder involving the deposition of senile plaques in the brain. The plaques consist of aggregates of a 
4 kDa Aβ-amyloid peptide (Aβ). The peptide is produced by sequential cleavage of the amyloid 
precursor protein (APP) by β- and γ-secretases [45,46]. The level of β-amyloid peptide, one of the 
major components of toxic amyloid plaques, depends directly on the hydrolytic activity of β-secretase. 
Nawrot et al. designed RNA-cleaving ribozymes in order to control the expression of β-secretase. The 
scientific findings demonstrated that these ribozymes were able to significantly inhibit β-secretase 
gene expression at both the mRNA and protein levels [46]. Furthermore, the inhibition of β-site APP 
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cleaving enzyme influenced the total population of β-amyloid peptide and as a result, it can be 
considered as a molecular tool for the anti-amyloid treatment of AD disease.  
In another study, Kanamori et al. showed that an mRNA transcribed in dihydrolipoamide 
succinyltransferase (DLST) gene was significantly lower in the brain of AD patients compared to the 
controls [47]. The truncated gene product (designated MIRTD) localized to the intermembrane space 
of mitochondria. A dimeric hammerhead ribozyme (maxizyme) was targeted against the MIRTD 
transcript. SH-SY5Y neuroblastoma cells transfected with maxizyme constructs reduced MIRTD 
expression. The ribozyme-expressing cells had a greater sensitivity to hydrogen peroxide and a 
significantly reduced rate of respiration, implicating MIRTD in the assembly of the cytochrome C 
oxidase complex, whose defect has been a candidate of the causes of AD [47,48]. 
Data from another AD study implicated the double-stranded RNA dependent protein kinase (PKR) 
in disease progression [49]. A library of hammerhead ribozyme genes was employed to identify genes 
involved in tunicamycin-induced apoptosis of SK-N-SH cells. Results from screening the ribozyme 
library led to the identification of PKR, which subsequently was found to be elevated in the brains of 
AD patients. 
Parkinson’s disease (PD) is another neurodegenerative disorder which is characterized by selective 
degeneration of substantia nigra dopamigenic neurons and the presence of abnormal cytoplasmic 
aggregates of a-synuclein [50]. Scientific reports showed that a-synuclein overexpression creates toxic 
effects to dopaminergic neurons [51,52]. By contrast, down-regulation of a-synuclein is effective for 
inhibition of progressive pathogenesis of PD. Hayashita-Kinoh et al. used adeno-associated virus 
(AAV) vector delivery of a-synuclein ribozyme in order to test its silencing effect on degenerating 
nigrostriatal neurons in a PD animal model, expressing the 1-methyl-4-phenylpyridinium (MPP+) [53]. 
MPP+ is a neurotoxic compound found in dopaminergic neurons and is responsible for up-regulation 
of a-synuclein [54]. Hayashita-Kinoh et al. designed a ribozyme against human a-synuclein gene 
expression and constructed a ribozyme-expressing rAAV vector (designated rAAV-SynRz). Co-
transfection of rAAV-SynRz and rAAV-a-synuclein into HEK293 cells resulted in down-regulation of 
a-synuclein protein expression in vitro. rAAV-SynRz was then injected into the substantia nigra of 
MPP+-treated rats. Cell counts of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra 
revealed that rAAV-SynRz significantly protected TH-positive cells against apoptotic death, compared 
with untransfected mice or those which were injected with a control reporter vector [53]. These results 
showed that the use of rAAV-SynRz allowed the survival of higher number of TH-positive neurons in 
substantia nigra in the MPP+ model. Furthermore, these results suggest that down-regulation of a-
synuclein expression could be a potentially suitable route for gene therapy of PD.  
Glioblastomas are the most frequent malignant brain tumors, which can progress from lower grade 
gliomas or arise de novo. Glioblastomas are lethal and nearly all patients die within one year, despite 
treatment [55]. Ribozymes and DNAzymes have been exploited to tackle glioblastoma through RNA-
targeted strategies [55,56]. 
The secreted growth factor pleiotrophin (PTN), also called heparin binding growth-associated 
molecule (HB-GAM), heparin affin regulatory peptide (HARP), heparin-binding growth factor 8, 
heparin-binding neurotrophic factor (HBNF), or osteoblast-specific protein-1 (OSF-1) is a 15.3-kDa 
developmentally regulated cytokine, which shows very limited expression in normal adult tissues, but 
is markedly upregulated in various primary human tumors and tumor cell lines [55,57]. Scientists have 
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tested the hypothesis that the growth of human glioblastomas can be controlled by regulating PTN 
expression. Grzelinski et al. showed in two cell lines, U87 and T98G, that stable ribozyme-targeting 
leads to a robust reduction of PTN mRNA and protein levels. Further investigations showed that the 
reduction of PTN mRNA and protein levels results in decreased migration and colony formation in 
both glioblastoma cell lines [55]. When the same strategy was followed in a mouse model, 
angiogenesis and tumor growth were markedly reduced upon PTN depletion, paralleled by decreased 
PTN serum levels [55]. In addition, PTN was found to signal through anaplastic lymphoma kinase 
(ALK) [58]. ALK was found to be upregulated in glioplastoma compared to normal brain and when 
bound to PTN growth stimulatory and antiapoptotic effects are mediated [59]. Grzelinski et al. used a 
subcutaneous tumor xenograft model in order to transfect specific ribozymes against both PTN and 
ALK, this had as a result the abolishment of tumor growth [60].  
Clinical and experimental evidence showed that the metastasis of malignant cells from a localized 
tumor is directly related to the number of microvessels in the primary tumor. Tumor angiogenesis is 
thought to be mediated by tumour-cell-derived growth factors. PTN can induce the release of active 
proteolytic enzymes from endothelial cells and induce tube formation of endothelial cells in vitro. It 
may well be able to serve as a tumor angiogenesis factor [61]. To test the above hypothesis, Czubayko 
et al. transfected human melanoma cells expressing high PTN levels, found to be able to metastasize 
from subcutaneous tumors to the lungs of experimental animals, with ribozymes in order to reduce 
PTN expression levels. The reduction of PTN mRNA levels showed not to affect the growth of the 
melanoma cells in vitro. In nude mice, however, tumor growth and angiogenesis were decreased. 
Moreover, apoptosis in the tumors was increased and the metastatic spread of tumors from the 
subcutaneous site to the lungs was prevented [62].  
Finally, DNAzymes were used against the Japanese encephalitis virus (JEV). JEV is an arthropod-
borne flavivirus with a single-stranded RNA genome containing non-coding regions at its 5' and 3'-
ends [63]. Non-coding regions have flavivirus-conserved sequences that are important for virus 
replication. As previously described, DNAzymes are single-stranded oligodeoxynucleotides (ODNs) 
with Mg2+-dependent enzymatic activity capable of cleaving single-stranded RNA at specific sites 
under simulated physiological conditions [64]. These DNAzymes were able to specifically target the 
NCRs and inhibit JEV replication in culture cells and infected animals [65]. Appaiahgari et al. showed 
that intra-cerebral administration of a poly-(G)(10)-tethered, phosphorothioated DNAzyme in JEV-
infected mice led to more than 99.99% inhibition of virus replication in brain, resulting in a dose-
dependent extended lifespan or complete recovery of the infected animals [65]. 
4. Conclusions  
To date, several different therapeutic attempts have been described as potential treatment 
approaches for many muscle and brain diseases. The use of catalytic nucleic acids and more 
specifically of ribozymes and DNAzymes against these diseases has shown some promise. Several 
approaches have already been described in the literature which reveal the potential of ribozymes and 
DNAzymes as tools for the study or therapy in muscle and brain diseases. The sequence-specific 
action which both of these categories of catalytic nucleic acids have against target RNA makes them 
flexible agents for the elimination or repair of pathological gene expression in muscle and brain cells. 
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Particularly the trans-splicing ribozyme has the unique feature to repair mutant transcripts which are 
implicated in both groups of diseases. Naturally, more effort should be dedicated, particularly in the 
area of delivery of nucleic acids so that the effect of both ribozymes and DNAzymes is more efficient 
and specific.  
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